So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Wegovy (semaglutide) is a GLP-1 receptor agonist that’s FDA ... Your healthcare provider will then guide you to slowly raise the amount each week until you reach the full dose of 3 mg daily. In a year ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago. GLP-1 agonist Wegovy ...

the pharmaceutical giant narrowing its full-year sales growth guidance while posting a 79% year-over-year sales increase for its landmark weight-loss drug Wegovy. Catalysts hosts Seana Smith and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the ...